High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR

被引:907
作者
Shields, RL
Namenuk, AK
Hong, K
Meng, YG
Rae, J
Briggs, J
Xie, D
Lai, J
Stadlen, A
Li, B
Fox, JA
Presta, LG
机构
[1] Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA
[2] Genentech Inc, Dept Bioanalyt Technol, San Francisco, CA 94080 USA
[3] Genentech Inc, Dept Analyt Chem, San Francisco, CA 94080 USA
[4] Genentech Inc, Dept Pharmacokinet & Metab, San Francisco, CA 94080 USA
关键词
D O I
10.1074/jbc.M009483200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Immunoglobulin G (IgG) Fc receptors play a critical role in linking IgG antibody-mediated immune responses with cellular effector functions. A high resolution map of the binding site on human IgG1 for human Fc gamma RI, Fc gamma RIIA, Fc gamma RIIB, Fc gamma RIIIA, and FcRn receptors has been determined. A common set of IgG1 residues is involved in binding to all Fc gammaR; Fc gamma RII and Fc gamma RIII also utilize residues outside this common set. In addition to residues which, when altered, abrogated binding to one or more of the receptors, several residues were found that improved binding only to specific receptors or simultaneously improved binding to one type of receptor and reduced binding to another type. Select IgG1 variants with improved binding to Fc gamma RIILA exhibited up to 100% enhancement in antibody-dependent cell cytotoxicity using human effector cells; these variants included changes at residues not found at the binding interface in the IgG/Fc gamma RIIIA co-crystal structure (Sondermann, P., Huber, R., Oosthuizen, V., and Jacob, U. (2000) Nature 406, 267-273). These engineered antibodies may have important implications for improving antibody therapeutic efficacy.
引用
收藏
页码:6591 / 6604
页数:14
相关论文
共 81 条
[1]   Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma [J].
Anderson, DR ;
GrilloLopez, A ;
Varns, C ;
Chambers, KS ;
Hanna, N .
BIOCHEMICAL SOCIETY TRANSACTIONS, 1997, 25 (02) :705-708
[2]  
Armour KL, 1999, EUR J IMMUNOL, V29, P2613, DOI 10.1002/(SICI)1521-4141(199908)29:08<2613::AID-IMMU2613>3.0.CO
[3]  
2-J
[4]   CRYSTAL-STRUCTURE OF THE COMPLEX OF RAT NEONATAL FC RECEPTOR WITH FC [J].
BURMEISTER, WP ;
HUBER, AH ;
BJORKMAN, PJ .
NATURE, 1994, 372 (6504) :379-383
[5]   MOLECULAR RECOGNITION OF ANTIBODY (IGG) BY CELLULAR FC RECEPTOR (FCRI) [J].
BURTON, DR ;
JEFFERIS, R ;
PARTRIDGE, LJ ;
WOOF, JM .
MOLECULAR IMMUNOLOGY, 1988, 25 (11) :1175-1181
[6]   THE BINDING-AFFINITY OF HUMAN-IGG FOR ITS HIGH-AFFINITY FC RECEPTOR IS DETERMINED BY MULTIPLE AMINO-ACIDS IN THE CH2 DOMAIN AND IS MODULATED BY THE HINGE REGION [J].
CANFIELD, SM ;
MORRISON, SL .
JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 173 (06) :1483-1491
[7]   DESIGNING CD4 IMMUNOADHESINS FOR AIDS THERAPY [J].
CAPON, DJ ;
CHAMOW, SM ;
MORDENTI, J ;
MARSTERS, SA ;
GREGORY, T ;
MITSUYA, H ;
BYRN, RA ;
LUCAS, C ;
WURM, FM ;
GROOPMAN, JE ;
BRODER, S ;
SMITH, DH .
NATURE, 1989, 337 (6207) :525-531
[8]   HUMANIZATION OF AN ANTI-P185HER2 ANTIBODY FOR HUMAN CANCER-THERAPY [J].
CARTER, P ;
PRESTA, L ;
GORMAN, CM ;
RIDGWAY, JBB ;
HENNER, D ;
WONG, WLT ;
ROWLAND, AM ;
KOTTS, C ;
CARVER, ME ;
SHEPARD, HM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (10) :4285-4289
[9]   IDENTIFICATION OF THE FC-GAMMA RECEPTOR CLASS-I BINDING-SITE IN HUMAN-IGG THROUGH THE USE OF RECOMBINANT IGG1/IGG2 HYBRID AND POINT-MUTATED ANTIBODIES [J].
CHAPPEL, MS ;
ISENMAN, DE ;
EVERETT, M ;
XU, YY ;
DORRINGTON, KJ ;
KLEIN, MH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (20) :9036-9040
[10]  
CHAPPEL MS, 1993, J BIOL CHEM, V268, P25124